Literature DB >> 10172460

The cost effectiveness of amoxicillin/clavulanic acid as antibacterial prophylaxis in abdominal and gynaecological surgery.

P G Davey1, S E Parker, I K Crombie, M Jaderberg.   

Abstract

The objective of this study was to compare the cost effectiveness of amoxicillin/clavulanic acid with other antibacterial regimens for prophylaxis of infection after elective abdominal or gynaecological surgery. Data from 21 previously published comparative clinical trials were used to calculate statistical confidence intervals for differences in postoperative wound infection rate. A simple model was used to produce a tabular sensitivity analysis of cost effectiveness over a wide range of costs of wound infection and potential differences in efficacy. For more expensive comparator regimens, including combination regimens utilising gentamicin and metronidazole, amoxicillin/clavulanic acid was either likely to be more cost effective or equally cost effective. For example, in trials of colonic surgery the comparators were on average 11.39 pounds more expensive than amoxicillin/clavulanic acid, which was > 95% likely to be more cost effective unless the cost of wound infection was estimated to be > 1519 pounds. Amoxicillin/clavulanic acid was more expensive than only 2 of the 21 comparators. Furthermore, in one of these 2 trials it was also significantly more effective than the comparator. In this trial, amoxicillin/clavulanic acid was > 95% likely to be more cost effective as prophylaxis in hysterectomy than rectal metronidazole, provided that the cost of wound infection was estimated to be > 179 pounds. In conclusion, this analysis shows that amoxicillin/clavulanic acid, given as monotherapy, is likely to be equally or more cost effective than a wide range of comparator regimens for prophylaxis of elective abdominal or gynaecological surgery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 10172460     DOI: 10.2165/00019053-199507040-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  23 in total

1.  Meta-analysis and quality of evidence in the economic evaluation of drug trials.

Authors:  R J Simes; P P Glasziou
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

2.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

3.  Metronidazole and Augmentin in the prevention of sepsis after appendicectomy.

Authors:  J Drumm; I A Donovan; R Wise; P Lowe
Journal:  Br J Surg       Date:  1985-07       Impact factor: 6.939

4.  Single-dose clavulanate-potentiated amoxycillin versus three-dose cefotaxime in the prevention of wound infection following elective cholecystectomy: a prospective randomized study.

Authors:  M B el Mufti; A Glessa
Journal:  J Int Med Res       Date:  1988 Mar-Apr       Impact factor: 1.671

5.  Amoxycillin-clavulanic acid (Augmentin) versus metronidazole as prophylaxis in hysterectomy: a prospective, randomized clinical trial.

Authors:  E M Brown; J Depares; A A Robertson; S Jones; A B Hughes; E C Coles; J R Morgan
Journal:  Br J Obstet Gynaecol       Date:  1988-03

6.  Cost-benefit analysis of cephradine and mezlocillin prophylaxis for abdominal and vaginal hysterectomy.

Authors:  P G Davey; I D Duncan; D Edward; A C Scott
Journal:  Br J Obstet Gynaecol       Date:  1988-11

7.  Prophylaxis in gynaecological surgery: a prospective randomized comparison between single dose prophylaxis with amoxycillin/clavulanate and the combination of cefuroxime and metronidazole.

Authors:  S Friese; F T Willems; S M Loriaux; J M Meewis
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

8.  A comparison between amoxycillin/clavulanate and mezlocillin in abdominal surgical prophylaxis.

Authors:  D Menzies; J M Gilbert; M J Shepherd; T R Rogers
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

9.  Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital.

Authors:  R W Haley
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

10.  Benefit-cost analysis of antimicrobial prophylaxis in abdominal and vaginal hysterectomy.

Authors:  M Shapiro; S C Schoenbaum; I B Tager; A Muñoz; B F Polk
Journal:  JAMA       Date:  1983-03-11       Impact factor: 56.272

View more
  3 in total

Review 1.  Cost-effective prophylaxis of surgical infections.

Authors:  S R Norrby
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

2.  Antibiotic policies. Economics and effectiveness from a UK perspective.

Authors:  P Davey
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  Using cost of infection as a tool to demonstrate a difference in prophylactic antibiotic efficacy: a prospective randomized comparison of the pharmacoeconomic effectiveness of ceftriaxone and cefotaxime prophylaxis in abdominal surgery.

Authors:  John C Woodfield; Andre M Van Rij; Ross A Pettigrew; Antje van der Linden; Donna Bolt
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.